[Pharmacokinetics and antimicrobial effect of cefminox in serum and ascitic fluid for experimental purulent peritonitis in mice].
An appropriate choice of antibiotics plays an important role in the treatment of purulent peritonitis. We examined the pharmacokinetics and antimicrobial effect of cefminox (CMNX) on experimental purulent peritonitis made by intraperitoneal injection of E. coli and/or B. fragilis in mice from elimination of bacteria in peripheral blood and ascitic fluid. 1) E. coli in blood and ascitic fluid decreased within one or two hrs after intravenous injection of CMNX or latamoxef (LMOX) in a dose of 25 or 100 mg/kg. The bacteria-elimination effect of CMNX was superior to that of LMOX. 2) Comparing with the effect of LMOX, B. fragilis in ascitic fluid acceleratively decreased in shorter period by the intravenous administration of CMNX. This indicated that peritoneal transfer of CMNX was better than that of LMOX. 3) Clearance of E. coli and B. fragilis from blood was accomplished by single dose (25 mg/kg) intravenous administration of CMNX, whereas it was not by the same dose of LMOX, resulting in LD50 of CMNX and LMOX were 5.0 and 39.3 mg/kg, respectively. Thus, we should select some antibiotics which shows good clearance of the causative organisms from blood and ascitic fluid as well as antimicrobial effect as a therapeutics for acute purulent peritonitis caused by E. coli and/or B. fragilis.
Azuma
Y
Y
Tanimura
H
H
Aoki
Y
Y
Isii
T
T
Goi
H
H
D000818:Animals; D001202:Ascitic Fluid / Q000378:metabolism*; D001424:Bacterial Infections; D001441:Bacteroides fragilis; D002513:Cephamycins / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004926:Escherichia coli; D008297:Male; D051379:Mice; D010538:Peritonitis / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism*; D013492:Suppuration
D002513:Cephamycins; C046079:cefminox